Prellis Biologics is an organ and tissue engineering company established in 2016 to revolutionize transplantation and donation with holographic bioprinting. It is dedicated to improving patients' lives by addressing challenges commonly faced in early-stage drug discovery and translational pharmacology.

Prellis Bio's two-photon holographic technology supports 3D printing of large, complex tissue co-culture systems, such as lymph node organoids that recapitulate human immune responses in vitro. The EXIS platform incorporates organoids for the discovery of fully human antibodies with broad genetic diversity in as little as three to four weeks. In addition, EXIS enables assessment of immunogenicity in response to therapeutic candidates. With EXIS, Prellis is able to exploit fully-human immune responses for a variety of applications including antibody discovery, immunogenicity assessment and tumor-immune models.